Free Trial
NASDAQ:RPRX

Royalty Pharma 8/7/2024 Earnings Report

Royalty Pharma logo
$32.64 +0.45 (+1.38%)
As of 02:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Royalty Pharma EPS Results

Actual EPS
-$0.40
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Royalty Pharma Revenue Results

Actual Revenue
$10.92 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Royalty Pharma Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Royalty Pharma's Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Remove Ads

Royalty Pharma Earnings Headlines

Royalty Pharma modifies acquisition agreement
Royalty Pharma appoints Biohaven CEO Vlad Coric to board
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Royalty Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Royalty Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Royalty Pharma and other key companies, straight to your email.

About Royalty Pharma

Royalty Pharma (NASDAQ:RPRX) operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

View Royalty Pharma Profile

More Earnings Resources from MarketBeat